Activist Investors Bid $2.25 Per Share to Take Over SEER
Activist investors offer to buy Seer for $2.25/share cash + CVR, criticize CEO, and push board to respond by Apr 22.
Already have an account? Sign in.
Activist investors offer to buy Seer for $2.25/share cash + CVR, criticize CEO, and push board to respond by Apr 22.
Tesla plans to unveil a redesigned next-generation Roadster as early as August, featuring a limited-edition model with SpaceX cold-gas thrusters for extreme acceleration and brief hovering.
Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.